ADRB2 and breast cancer: Regarding the BC, propranolol-treated patients (but not β1-selective blocker atenolol-treated patients) were less likely to present with advanced-stage tumors and showed better prognosis than non-users, suggesting that the blockage of β2-AR contributed to the anticancer effects of propranolol [8].